Skip to main navigation
Skip to content

Top Bar

  • info@eledon.com
  • +1 949.238.8090

Main navigation

  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Governance
  • R&D
    • R&D Overview
    • CD40L Pathway
    • Pipeline
    • AT-1501
    • Phase 1 KLH Challenge
  • Investors
    • News
    • Events
    • Presentations
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
    • Contact
  • Join the team
  • Contact Us

Investors

Investor Relations

  • Investors
  • News
  • Events
  • Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor FAQs
  • Contact Investor Relations

News


Date Title
06/01/2020 Summary ToggleNovus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
05/15/2020 Summary ToggleNovus Therapeutics Reports First Quarter 2020 Financial Results
03/17/2020 Summary ToggleNovus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
03/02/2020 Summary ToggleNovus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
01/13/2020 Summary ToggleNovus Therapeutics Provides Update on OP0201
01/10/2020 Summary ToggleNovus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
11/29/2019 Summary ToggleNovus Therapeutics to Participate in Two Investor Conferences
11/13/2019 Summary ToggleNovus Therapeutics Reports Third Quarter 2019 Financial Results
10/29/2019 Summary ToggleNovus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
08/29/2019 Summary ToggleNovus Therapeutics to Participate in Two Upcoming Investor Conferences

Pagination

  • First page First
  • Previous page Previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 11 - 20 of 69 results

Toolkit

Print Page Email Alerts RSS Feeds Contact

Footer

Quick links

  • Home
  • About Us
  • CD40L Pathway
  • Pipeline
  • AT-1501
  • KLH Challenge
  • Contact Us

Footer Investor Links

 

  • Investors
  • Press Releases
  • Governance
  • Stock Information
  • SEC Filings
  • Investor Email List
© 2021 Eledon Pharmaceuticals, Inc. - All Rights Reserved.